These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for hepatobiliary cancers. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC)

MODULE 2: Selection and Sequencing of Therapies for Relapsed/Refractory HCC

MODULE 3: Current Treatment Strategies for Advanced Biliary Tract Cancers

MODULE 4: Future Directions in the Management of Biliary Tract Cancers

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.

Learning Objectives

• Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first- and later-line therapy for unresectable or metastatic hepatocellular carcinoma (HCC).
• Appreciate Phase III data leading to the FDA approval of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these can be optimally integrated into patient care.
• Evaluate the rationale for and available and emerging data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for patients with HCC, and determine the current and potential roles of these novel regimens.
• Establish an evidence-based approach to the selection and sequencing of therapeutic options for patients with progressive HCC.
• Discuss the biologic justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers, and review available and emerging data with anti-PD-1/PD-L1 antibody-based therapy.
• Recognize the molecular heterogeneity of cholangiocarcinomas and other biliary tract cancers, and appreciate the biologic rationale for efforts to exploit abnormalities documented in these diseases.
• Assess key data sets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
• Develop an understanding of published clinical trial findings with isocitrate dehydrogenase 1 (IDH1) inhibitors for advanced cholangiocarcinoma with an IDH1 mutation, and identify patients for whom treatment with this novel strategy is warranted.
• Maintain an understanding of the side effects and toxicities associated with targeted agents and immunotherapeutic approaches used in the management of advanced HCC and other biliary tract cancers, and intervene with early and effective responses to various adverse events.
• Recall current data with investigational agents and strategies in clinical testing for hepatobiliary cancers, and refer appropriate eligible patients for trial participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Abou-Alfa — Consulting Agreements: Adicet Bio, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, BeiGene Ltd, Berry Genomics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Servier Pharmaceuticals LLC, Silenseed Ltd, Sobi, Vector Pharma, Yiviva; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Group, Puma Biotechnology Inc, QED Therapeutics, Silenseed Ltd, Yiviva. Dr Kelley — Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Kinnate Biopharma, Merck; Advisory Board: Kinnate Biopharma; Advisory Board or Steering Committee (to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Research Funding (to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Uncompensated Service on IDMC: Genentech, a member of the Roche Group, Merck.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.